Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.

International journal of biological sciences - 1 Jan 2017

Wang Yanxiao, Hou Ning, Cheng Xuan, Zhang Jishuai, Tan Xiaohong, Zhang Chong, Tang Yuling, Teng Yan, Yang Xiao

Abstract excerpt

Previous studies have suggested that enhancer zeste homolog 2 (Ezh2), a histone methyltransferase subunit of polycomb repressive complex 2 (PRC2), acts as an oncogene in lung adenocarcinoma (ADC) development. However, we found that in human lung ADC samples, deletion and mutations of EZH2 were also frequently present, with 14% of patients harboring loss-of-function EZH2 alterations. To explore the effect of Ezh2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to In Vitro Techniques

Share to Interleukin-6

Share to Polycomb Repressive Complex 2

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 28539837
DOI: 10.7150/ijbs.19108
PMCID: PMC5441181

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.PMID 28539837Read ↗

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.Semantic proximity Read ↗

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltratesSemantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic CancerSemantic proximity Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinomaSemantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerSemantic proximity Read ↗

Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.